噻唑,4-(氯甲基)-5-甲基- | 72438-01-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 中文名称: 噻唑,4-(氯甲基)-5-甲基-
• 英文名称: Pivaloyltaurine
• 英文别名: 2-(2,2-dimethylpropanoylamino)ethanesulfonic acid
• CAS: 72438-01-8
• 化学式: C₇H₁₅NO₄S
• 分子量: 209.27
• InChiKey: LEVAVHCQONHMEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• CORROLES FOR TREATING POXVIRUS INFECTION
  申请人：Université de Bourgogne

  公开号：EP3492079A1

  公开（公告）日：2019-06-05

  The present invention is related to a family of corroles for their use in the treatment of an infection by poxvirus.

  本发明涉及一类卡罗尔家族，用于治疗痘病毒感染。
• ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20180099957A1

  公开（公告）日：2018-04-12

  The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

  本发明提供了一种化合物的公式I，包括这些化合物的药物组合物以及使用这些化合物预防或治疗FXR介导或TGR5介导的疾病或症状的方法。
• Chain transfer agents for raft polymerization in aqueous media
  申请人：McCormick L. Charles

  公开号：US20070123670A1

  公开（公告）日：2007-05-31

  Polymers and copolymers synthesized by means that yield a narrow range of molecular weights can have different properties than polymers synthesized by conventional means. In order to obtain such polymers, however, polymerization must be controlled. One type of controlled polymerization is the reversible addition-fragmentation chain transfer (RAFT) process, which has characteristics of a living polymerization. The present invention discloses a group of dithioesters and trithioesters suitable as chain transfer agents for RAFT polymerization. The present invention also discloses RAFT polymerizations conducted in aqueous media.

  通过产生分子量窄范围的手段合成的聚合物和共聚物可能具有不同于传统手段合成的聚合物的性质。然而，为了获得这种聚合物，聚合必须受到控制。一种受控聚合的类型是可逆加成-断裂链转移（RAFT）过程，具有活性聚合的特征。本发明揭示了一组二硫代酯和三硫代酯，适用于RAFT聚合的链转移剂。本发明还揭示了在水介质中进行的RAFT聚合。
• Isoxazole analogs as FXR agonists and methods of use thereof
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10450306B2

  公开（公告）日：2019-10-22

  The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

  本发明提供了式 I 的化合物、 包含这些化合物的药物组合物，以及使用这些化合物预防或治疗 FXR 介导或 TGR5 介导的疾病或病症的方法。
• Pentacyclic triterpene compound and preparation method therefor, and pharmaceutical composition and use thereof
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US11192916B2

  公开（公告）日：2021-12-07

  Disclosed are a pentacyclic triterpene compound as shown in general formula (I) and a preparation method therefor. The compound has an effective antagonistic effect on FXR receptors.

  本发明公开了通式（I）所示的五环三萜化合物及其制备方法。该化合物对 FXR 受体具有有效的拮抗作用。